Skip to content

A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema

Hand Eczema Trial: A Randomised Clinical Trial of the Effect of Classification and Individual Counselling Among Health Care Workers With Hand Eczema

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01012453
Acronym
HET
Enrollment
300
Registered
2009-11-13
Start date
2009-10-31
Completion date
Unknown
Last updated
2009-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatitis, Eczema, Skin Disease

Keywords

Hand eczema, Hand dermatitis, Occupational skin disease, skindisease in health care workers, occupational hand dermatitis, occupational hand eczema

Brief summary

Objectives and perspective: 1. To estimate the prevalence of hand eczema in a cohort of health care workers and assess exposures in the hospital environment that can lead to hand eczema . To investigate the knowledge of skin protection among health care workers. 2. To classify subtypes of hand eczema, assess severity of hand eczema and quality of life in health care workers with hand eczema 3. To evaluate the effect of a combination of classification of hand eczema and individual work-related counseling in skin protective behavior. The overall perspective of the trial is to develop new strategies for prevention of occupational hand eczema in health care workers. Hypotheses: * Irritant contact dermatitis is more common than allergic contact dermatitis. * The combination of precise classification (subtyping of HE) and individual counseling will have a positive impact on the prognosis of hand eczema. * The positive impact on the prognosis of hand eczema will have a positive impact on quality of life (QoL). * The knowledge of protective behavior will increase. * Education in a skin care program will have a positive impact on skin protective behavior.

Interventions

BEHAVIORALA randomised clinical trial of the effect of classification and individual counselling

The trial to be conducted is a randomised single-blinded parallel study. It is divided in two stages, T = 0 and follow-up at T = 6 months. All included participants will have a clinical examination at the beginning and at follow-up in the trial. Half of the participants will be randomised to intervention, the other half to control. The participants in the intervention group will, after the first clinical examination, pass on directly to the intervention which includes an allergological examination (patch and prick testing). Three days later they will be examined by a physician who will interpret the patch test and give a thorough, individual guidance in skin protection and occupational safety. The clinical examination of all participants at follow-up will reveal the difference in outcomes in the intervention and the control group.

Sponsors

The Danish Working Environment Authority
CollaboratorUNKNOWN
Region Zealand
CollaboratorOTHER
Zealand University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Participants will be recruited on the basis of the results from the questionnaire investigation of 3,181 HCW in three Danish hospitals in the same region. Participants who have answered yes to the validated question Have you had hand eczema within the past twelve months? will be invited to take part in the clinical trial. * Informed written consent must be present in order to participate.

Exclusion criteria

* Pregnancy * Systemic use of immunosuppressive drugs * Systemic use of retinoids * Active psoriatic lesions on the hands * Any serious medical condition which, in the opinion of the investigator, may interfere with the evaluation of the results * Lack of informed written consent

Design outcomes

Primary

MeasureTime frame
Primary outcome: Objective assessment of disease severity (HE), measured by HECSI-score at time = 6 months versus HECSI-score at time = 0.6 months

Secondary

MeasureTime frame
Secondary outcomes: -Subjective assessment of disease severity (HE) -Number of eruptions through the past three months -Knowledge of skin protection -Skinprotective behaviour -Quality of life6 months

Countries

Denmark

Contacts

Primary ContactKristina Sophie Ibler, MD, Ph.d-student
ksi@regionsjaelland.dk+45-47322600
Backup ContactTove Agner, MD, DM Science

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026